Primecap Management Co. CA Decreases Position in OraSure Technologies, Inc. (NASDAQ:OSUR)

Primecap Management Co. CA lowered its stake in OraSure Technologies, Inc. (NASDAQ:OSUR - Free Report) by 52.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 336,300 shares of the medical instruments supplier's stock after selling 371,850 shares during the period. Primecap Management Co. CA owned 0.45% of OraSure Technologies worth $1,214,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in OSUR. BNP Paribas Financial Markets raised its stake in OraSure Technologies by 27.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 855,951 shares of the medical instruments supplier's stock worth $3,655,000 after acquiring an additional 183,191 shares during the last quarter. Principal Financial Group Inc. raised its stake in shares of OraSure Technologies by 10.7% in the fourth quarter. Principal Financial Group Inc. now owns 73,137 shares of the medical instruments supplier's stock worth $264,000 after purchasing an additional 7,077 shares during the last quarter. Franklin Resources Inc. lifted its holdings in shares of OraSure Technologies by 28.5% during the third quarter. Franklin Resources Inc. now owns 269,269 shares of the medical instruments supplier's stock worth $1,091,000 after purchasing an additional 59,723 shares during the period. JPMorgan Chase & Co. boosted its position in OraSure Technologies by 5.8% in the third quarter. JPMorgan Chase & Co. now owns 847,933 shares of the medical instruments supplier's stock valued at $3,621,000 after buying an additional 46,216 shares during the last quarter. Finally, Barclays PLC increased its holdings in OraSure Technologies by 182.6% in the 3rd quarter. Barclays PLC now owns 195,793 shares of the medical instruments supplier's stock worth $836,000 after buying an additional 126,503 shares during the period. 93.50% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Insider Transactions at OraSure Technologies

In other news, Director John P. Kenny purchased 47,659 shares of the stock in a transaction that occurred on Thursday, February 27th. The shares were purchased at an average cost of $3.17 per share, with a total value of $151,079.03. Following the completion of the acquisition, the director now owns 70,915 shares of the company's stock, valued at approximately $224,800.55. This represents a 204.93 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Kenneth J. Mcgrath acquired 64,000 shares of the business's stock in a transaction on Thursday, February 27th. The stock was purchased at an average cost of $3.15 per share, with a total value of $201,600.00. Following the acquisition, the chief financial officer now directly owns 371,013 shares of the company's stock, valued at $1,168,690.95. This represents a 20.85 % increase in their position. The disclosure for this purchase can be found here. Insiders have bought 190,284 shares of company stock valued at $600,348 in the last 90 days. 3.40% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Separately, StockNews.com downgraded shares of OraSure Technologies from a "buy" rating to a "hold" rating in a report on Tuesday, March 4th.

OraSure Technologies Stock Up 6.4 %

Shares of OSUR traded up $0.22 during mid-day trading on Monday, reaching $3.66. The company had a trading volume of 1,499,365 shares, compared to its average volume of 865,985. The stock has a 50 day moving average of $3.71 and a two-hundred day moving average of $3.91. The stock has a market capitalization of $273.77 million, a P/E ratio of 24.40 and a beta of -0.02. OraSure Technologies, Inc. has a 52-week low of $2.69 and a 52-week high of $6.38.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.